Wow. Well, you know, we must ensure that drug companies do not rely on tricks in order to avoid competition.

Despite these wins, there is more that we need to do to reduce exorbitant drug prices for all Americans.

So last year, Congress passed the Inflation Reduction Act, which finally gives HHS the authority to negotiate drug prices for a select number of high-priced brand-name drugs.

Since Medicare was established in 1965, it has not covered routine dental benefits.

CMS should absolutely finalize this rule. But I want to argue here that CMS needs to go further and end these insurance industry scams.

Or we can spend nearly a trillion dollars in overpayments to insurance companies for crummy coverage that beneficiaries do not use.

The name of the game is volume. The more volume a drug company has with a particular PBM, and the greater the drug company's market share, the better the potential deal that the drug company can offer as an inducement to disfavor rival…

More than three out of four new patent applications for pharmaceuticals are for existing drugs.

Despite these wins, there is more that we need to do to reduce exorbitant drug prices for all Americans.

But we also cannot lose sight of the ways that drug companies continue to abuse our intellectual property laws to drive out competition.

So last year, Congress passed the Inflation Reduction Act, which finally gives HHS the authority to negotiate drug prices for a select number of high-priced brand-name drugs.